The unexpectedly high diversity and rate of evolution of UPEC are contributing to the difficulty in understanding molecular mechanisms underlying recurrent UTI. Advances in sequencing, algorithm development, and computing power provide an opportunity to elucidate the genetic and molecular basis for recurrent UTI using comparative genomics. The work proposed in Project 3 for the next funding period is designed to capitalize on the complementary expertise and biospecimen resources available in this SCCOR program. Gut and urine-associated E. coli strains recovered from three patients with recurrent UTI, enrolled in the clinical trial described in Project 2, will be selected and sequenced using the highly parallel 454 pyrosequencer. The sequence data will be used to examine E. coli evolution within a given individual, in two host habitats, over the course of three separate episodes of infection, and between different individuals. Follow-up studies will involve (i) quantitation of gene prevalence in isolates recovered from the two ecosystems (using new comparative pan-genomic methods and PCR-based sequence surveys), (ii) resequencing of genes statistically enriched in urine isolates to determine, based on maximum likelihood and parsimony algorithms, whether they are under positive selection in UPEC strains;and (iii) performing functional annotations. Genes that are (i) more prevalent in urine isolates than in fecal isolates within individual patients;(ii) more prevalent in UPEC strains than non-UPEC strains in a broad panel of clinical isolates;(iii) under positive selection in UPEC strains;and (iv) have functional annotations suggestive of a role in pathogenesis will be tested in a mouse model of UTI in collaboration with Project 1.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Specialized Center (P50)
Project #
5P50DK064540-09
Application #
8120694
Study Section
Special Emphasis Panel (ZRG1)
Project Start
Project End
Budget Start
2010-08-01
Budget End
2011-07-31
Support Year
9
Fiscal Year
2010
Total Cost
$293,904
Indirect Cost
Name
Washington University
Department
Type
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Yarbrough, Melanie L; Briden, Kelleigh E; Mitsios, John V et al. (2018) Mass spectrometric measurement of urinary kynurenine-to-tryptophan ratio in children with and without urinary tract infection. Clin Biochem 56:83-88
Spaulding, Caitlin N; Schreiber 4th, Henry Louis; Zheng, Weili et al. (2018) Functional role of the type 1 pilus rod structure in mediating host-pathogen interactions. Elife 7:
Shen, Jiangchuan; Walsh, Brenna J C; Flores-Mireles, Ana Lidia et al. (2018) Hydrogen Sulfide Sensing through Reactive Sulfur Species (RSS) and Nitroxyl (HNO) in Enterococcus faecalis. ACS Chem Biol 13:1610-1620
Rosen, David A; Twentyman, Joy; Hunstad, David A (2018) High Levels of Cyclic Di-GMP in Klebsiella pneumoniae Attenuate Virulence in the Lung. Infect Immun 86:
Olson, Patrick D; McLellan, Lisa K; Hreha, Teri N et al. (2018) Androgen exposure potentiates formation of intratubular communities and renal abscesses by Escherichia coli. Kidney Int 94:502-513
Ohlemacher, Shannon I; Giblin, Daryl E; d'Avignon, D André et al. (2017) Enterobacteria secrete an inhibitor of Pseudomonas virulence during clinical bacteriuria. J Clin Invest 127:4018-4030
Schreiber 4th, Henry L; Spaulding, Caitlin N; Dodson, Karen W et al. (2017) One size doesn't fit all: unraveling the diversity of factors and interactions that driveE. coliurovirulence. Ann Transl Med 5:28
Koh, Eun-Ik; Robinson, Anne E; Bandara, Nilantha et al. (2017) Copper import in Escherichia coli by the yersiniabactin metallophore system. Nat Chem Biol 13:1016-1021
Olson, Patrick D; McLellan, Lisa K; Liu, Alice et al. (2017) Renal scar formation and kidney function following antibiotic-treated murine pyelonephritis. Dis Model Mech 10:1371-1379
Spaulding, Caitlin N; Klein, Roger D; Ruer, Ségolène et al. (2017) Selective depletion of uropathogenic E. coli from the gut by a FimH antagonist. Nature 546:528-532

Showing the most recent 10 out of 140 publications